Recent advances in understanding cholangiocarcinoma

Area of Science:

• Oncology
• Gastroenterology
• Molecular Biology

Background:

• Cholangiocarcinoma (CCA) comprises tumors from bile duct epithelium, including intrahepatic (ICCA) and extrahepatic (ECCA) subtypes.
• The incidence of ICCA and ECCA has risen in recent decades.
• Molecular advancements have clarified distinctions between ICCA and ECCA, enabling personalized therapeutic approaches.

Purpose of the Study:

• To review recent molecular landscape progress in cholangiocarcinoma.
• To discuss emerging biomarker-guided treatment strategies.
• To provide future insights into managing advanced cholangiocarcinoma.

Main Methods:

• Literature review of recent molecular and clinical studies on cholangiocarcinoma.
• Analysis of emerging biomarkers and targeted therapies.
• Synthesis of current knowledge and future directions in CCA management.

Main Results:

• Significant progress in understanding the molecular heterogeneity of CCAs.
• Identification of potential biomarkers for guiding treatment decisions.
• Emerging targeted therapies showing promise in clinical trials.

Conclusions:

• Molecular insights are crucial for differentiating and treating ICCA and ECCA.
• Biomarker-guided strategies represent the future of personalized cholangiocarcinoma therapy.
• Continued research is essential for improving outcomes in advanced CCA.